PHASE II TRIAL ASSESS SFTY OF IMNOSPRSN W/DRAWAL IN LIVER TRNSPLNT RECIP W/HEP C

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。这是一项前瞻性多中心、开放标签、随机试验，丙型肝炎相关肝功能衰竭患者接受肝移植，并接受他克莫司和皮质类固醇的免疫抑制诱导。移植后3个月皮质类固醇逐渐减少，继续使用他克莫司。参与者定期评估肝炎复发和同种异体移植排斥反应的证据。移植后一年，适合停药的参与者被随机分配到免疫抑制停药组或维持组。被分配到戒断的参与者在1年内按计划逐渐减少。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a prospective multicenter, open-label, randomized trial in which participants with hepatitis C-related liver failure undergo liver transplantation and receive immunosuppression induction with tacrolimus and corticosteroids. Corticosteroids are tapered in the 3 months after transplantation and tacrolimus is continued. Participants are regularly assessed for recurrence of hepatitis and for evidence of allograft rejection. One year after transplantation, participants suitable for withdrawal are randomly assigned to immunosuppression withdrawal or maintenance. Participants assigned to withdrawal undergo a scheduled taper over 1 year.